W. K. A. Yung

TL;DR: Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 months in the PCB group, and freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received.

TL;DR: Treatment with TMZ was associated with improvement in HRQOL scores compared with treatment with PCB, and delaying disease progression by treatment with TMZ is beneficial to theHRQOL status of patients with recurrent GBM.

TL;DR: In general, patients and their significant others provide similar ratings of the patients' quality of life and discrepancies between patient-proxy ratings should not be interpreted, a priori, as evidence of the inaccuracy or biased nature of proxy-generated data.

TL;DR: Results indicate that E2F-T has anti-glioma activity in vitro and in vivo and that adenovirus-mediated p53 gene transfer is ineffective in causing apoptosis in glioma cells that retain a wild-type p53 genotype.

TL;DR: There are significant differences inHQL between patients with newly-diagnosed and recurrent braincancer and between Patients with differing KPS andBADLI scores and those capable of independent activities of daily living had higher functioning scores and less fatigue than did those who were not independent.